Syndax Pharmaceuticals (SNDX) Misses Q4 EPS by 2c, Miss on Revenues

Note: EPS may not be comparable

Syndax Pharmaceuticals (NASDAQ: SNDX) reported Q4 EPS of ($0.80), $0.02 worse than the analyst estimate of ($0.78). Revenue for the quarter came in at $1.19 million versus the consensus estimate of $1.65 million.

For earnings history and earnings-related data on Syndax Pharmaceuticals (SNDX) click here.

You May Also Be Interested In

• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
• Laser Photonics Corporation (LASE) Reports Q2 Loss of $0.08
• Nuvve Holdin (NVVE) Misses Q2 EPS by 1445c